ESMO 2023 preview – Pluvicto splashes down among the late-breakers
Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.
Novartis goes 0 for 2 in PD-1 blockade
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.
12 years on, Jakafi faces serious JAK competition
Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.
No keeping the red light on for Sting
CuraDev and OncoNano move into phase 1, trying to avoid the negative precedent of other Sting agonist projects.
Point looks to make a year-end Splash
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.
Despite the setbacks, interest in TGF-β remains
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
